The possible of immunotherapy for COVID-19: a systematic review

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorAminJafari, Akram-
Autor(es): dc.creatorGhasemi, Sorayya-
Data de aceite: dc.date.accessioned2026-02-09T11:32:46Z-
Data de disponibilização: dc.date.available2026-02-09T11:32:46Z-
Data de envio: dc.date.issued2020-04-15-
Data de envio: dc.date.issued2020-04-15-
Data de envio: dc.date.issued2020-06-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/40094-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S1567576920309127-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1142227-
Descrição: dc.descriptionThe novel coronavirus (2019-nCoV) is an emerging pathogen that was first described in late December 2019 and causes a severe respiratory infection in humans. Since the outbreak of COVID-19, international attention has raised to develop treatment and control options such as types of immunotherapies. The immunotherapy is an effective method for fighting against similar viral infections such as SARS-CoV, and MERS-CoV. These methods include several types of vaccines, monoclonal antibody candidates, and etc. This systematic review article was designed to evaluate the existing evidence and experience related to immunotherapy for 2019-nCoV. Web of Science (ISI), PubMed, and Scopus databases were used to search for suitable keywords such as 2019-nCoV, novel coronavirus, Immunotherapy, interleukin, vaccine and the related words for relevant publications up to 24.3.2020. The present systematic review was performed based on PRISMA protocol. Data extraction and quality valuation of articles were performed by two reviewers. 51 articles were the results of the search and based on the inclusions and exclusions criteria, 7 articles were included in the final review. As a conclusion of these studies demonstrated that although no serious research has been done on this subject at the time of writing this article, similar studies on the related viruses showed notable results. So immunotherapy for this virus can also be a suitable option.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceInternational Immunopharmacology-
Palavras-chave: dc.subject2019-nCoV-
Palavras-chave: dc.subjectCOVID-19-
Palavras-chave: dc.subjectImmunotherapy-
Palavras-chave: dc.subjectMonoclonal antibody-
Palavras-chave: dc.subjectVaccine-
Palavras-chave: dc.subjectInterleukin-
Título: dc.titleThe possible of immunotherapy for COVID-19: a systematic review-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.